TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1833543

Group type: EXPERIMENTAL
Intervention: 5 ml lignocaine, 0.5% (L) in rheumatology setting
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5 ml isotonic saline (S) in rheumatology setting
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5 ml lignocaine, 0.5% (L) in general practice setting
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5 ml isotonic saline (S) in general practice setting
Number of subjects: 41
Study: 6345489

Group type: EXPERIMENTAL
Intervention: Chemotherapy adjuvant administered prior to definitive irradiation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Oropharynx patients (T3-4 primaries)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Oral cavity tumors (T3-4 primaries)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patients with controlled primary and cervical nodes
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: N0 patients with oropharyngeal cancers
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: N3 nodes associated with primaries
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: N3 oropharyngeal deposits
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: N3 nodes secondary to oral cavity primaries
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Initial T or N-stage
Number of subjects: 500
Study: 31111942

Group type: EXPERIMENTAL
Intervention: Antimonials (one to two courses)
Number of subjects: 48
Study: 28295985

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 622

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 622
Study: 26349872

Group type: EXPERIMENTAL
Intervention: Central venous access devices (CVADs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical staff perspectives
Number of subjects: 32
Study: 22937895

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg once weekly
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once weekly
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Insulin glargine once daily
Number of subjects: 1049
Study: 21269722

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination at 0, 1, 4 and 8 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Classic vaccination at 0, 1 and 6 months
Number of subjects: 180
Study: 19969179

Group type: EXPERIMENTAL
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard walking exercises
Number of subjects: 21
Study: 17596432

Group type: EXPERIMENTAL
Intervention: Vaccination with HPV L1 VLP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15577784

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11265884

Group type: EXPERIMENTAL
Intervention: Tunneled pleural catheters (TPCs)
Number of subjects: 28
Study: 9233203

Group type: EXPERIMENTAL
Intervention: Breast cleansing with Phisoderm and tap water
Number of subjects: 178

Group type: COMPARATOR
Intervention: Breast cleansing with tap water only
Number of subjects: 178
Study: 8425992

Group type: EXPERIMENTAL
Intervention: Quantitative angiographic variable - minimal lumen diameter
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Quantitative angiographic variable - percent diameter stenosis
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Quantitative angiographic variable - change in minimal lumen diameter
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Quantitative angiographic variable - change in percent diameter stenosis
Number of subjects: 350
Study: 2831117

Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg/day for 8 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study: 31786590

Group type: EXPERIMENTAL
Intervention: Vegetarian lunch-default (Group 2)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Non-vegetarian lunch-default (Group 1)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nudge acceptance
Number of subjects: 330
Study: 30105460

Group type: EXPERIMENTAL
Intervention: Lapatinib with ECF/X
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo with ECF/X
Number of subjects: 28
Study: 27230046

Group type: EXPERIMENTAL
Intervention: HMI + PCI (high mechanical index impulses + percutaneous coronary intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HMI + PCI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LMI + PCI (low mechanical index imaging + percutaneous coronary intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCI only (percutaneous coronary intervention)
Number of subjects: 100
Study: 23591152

Group type: EXPERIMENTAL
Intervention: Dairy snacks (plain yogurt, plain yogurt with honey, strawberry yogurt, skim milk)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skim milk (lowest protein to carbohydrate ratio)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orange juice (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dairy snacks (increased protein to carbohydrate ratio)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 20
Study: 23022672

Group type: COMPARATOR
Intervention: aripiprazole (3-30 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: perospirone (8-48 mg/day)
Number of subjects: 58
Study: 20861007

Group type: EXPERIMENTAL
Intervention: Danoprevir (100, 200 mg every 12 h or 8 h for 14 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18456940

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture treatment (AAT) on active points
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham acupuncture treatment (AAT on sham points)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (AAT and sham)
Number of subjects: 28
Study: 17135738

Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) for 52 weeks
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Alternating group (two-compound product and calcipotriol) for 52 weeks
Number of subjects: 634

Group type: COMPARATOR
Intervention: Calcipotriol for 48 weeks after 4 weeks of two-compound product
Number of subjects: 634
Study: 14564144

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (including ACE inhibitors, diuretics, digoxin)
Number of subjects: 0
Study: 10714842

Group type: EXPERIMENTAL
Intervention: Diclofenac 2-3 mg kg(‐1) 24 h(‐1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Acetaminophen 90 mg kg(‐1) 24 h(‐1)
Number of subjects: 48
Study: 9186890

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH; N = 30)
Number of subjects: 44

Group type: COMPARATOR
Intervention: no treatment (N = 14)
Number of subjects: 44
Study: 1389194

Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg
Number of subjects: 61
Study: 3157384

Group type: EXPERIMENTAL
Intervention: Thymostimulin (Tp-1 Serono)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with histiocytosis-X
Number of subjects: 101
Study: 31464384

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 42
Study: 29349712

Group type: COMPARATOR
Intervention: RT-HIIT
Number of subjects: 240

Group type: COMPARATOR
Intervention: AT-HIIT
Number of subjects: 240
Study: 28454832

Group type: EXPERIMENTAL
Intervention: Selective catheterization strategy (initial CCTA followed by ICA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct catheterization strategy (direct ICA)
Number of subjects: 0
Study: 26340009

Group type: EXPERIMENTAL
Intervention: Scalloped implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flat implants
Number of subjects: 40
Study: 24192331

Group type: COMPARATOR
Intervention: Obese patients (BMI 30.0 to 34.9)
Number of subjects: 5683

Group type: COMPARATOR
Intervention: Severely obese patients (BMI ≥ 35)
Number of subjects: 5683
Study: 21447019

Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Probiotic-free artichokes (control)
Number of subjects: 20
Study: 18419482

Group type: EXPERIMENTAL
Intervention: Moxifloxacin monotherapy (400 mg once per day)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Ceftriaxone plus levofloxacin combination therapy
Number of subjects: 733
Study: 16843075

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14656349

Group type: EXPERIMENTAL
Intervention: Active sublingual immunotherapy (SLIT) combined with inhaled fluticasone (S+F)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Placebo sublingual immunotherapy combined with inhaled fluticasone (placebo S+F)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 38
Study: 10391417

Group type: EXPERIMENTAL
Intervention: 4-AP 30 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: 4-AP 6 mg/day (active-treatment control)
Number of subjects: 21
Study: 8681509

Group type: EXPERIMENTAL
Intervention: Lexical naming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular naming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lexical decision task
Number of subjects: 0
Study: 1641760

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 10 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard intensive care unit support
Number of subjects: 100
Study: 6873132

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metoprolol 200 mg/day
Number of subjects: 50
Study: 31685213

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (PI)
Number of subjects: 2841

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 2841
Study: 29472415

Group type: EXPERIMENTAL
Intervention: ClearGuard HD antimicrobial barrier caps
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Tego hemodialysis connectors plus Curos disinfecting caps
Number of subjects: 1671
Study: 26961929

Group type: EXPERIMENTAL
Intervention: DHA plus EPA (2 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24505290

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 22062358

Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 20710062

Group type: EXPERIMENTAL
Intervention: Pretreatment fasting lipid parameters (total cholesterol, LDL, HDL, apoB, TG)
Number of subjects: 315
Study: 17129234

Group type: EXPERIMENTAL
Intervention: Topical eutectic mixture for premature ejaculation (TEMPE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15889624

Group type: EXPERIMENTAL
Intervention: Normative information only
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Normative information plus self-focusing comparison to one's drinking
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Normative information (both contexts)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Normative information plus self-focus
Number of subjects: 230

Group type: COMPARATOR
Intervention: Public versus private measurement
Number of subjects: 230
Study: 11906518

Group type: EXPERIMENTAL
Intervention: Epileptic seizures (EP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonepileptic seizures (NES)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (EP and NES)
Number of subjects: 48
Study: 11313161

Group type: EXPERIMENTAL
Intervention: 1 mg clonazepam
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9235548

Group type: EXPERIMENTAL
Intervention: rHu-EPO (2000-4000 IU/week for 6 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (-EPO)
Number of subjects: 23
Study: 8426544

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (MIC)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-intensity cycling (HIC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal sedentary activity
Number of subjects: 14
Study: 3808791

Group type: EXPERIMENTAL
Intervention: Solution A (WHO-recommended oral rehydration solution) containing Na+ 90 mmol/L
Number of subjects: 62

Group type: COMPARATOR
Intervention: Solution B (Pedialyte RS) containing Na+ 75 mmol/L
Number of subjects: 62
Study: 31743094

Group type: EXPERIMENTAL
Intervention: Walking group sessions (40-50 min duration)
Number of subjects: 26
Study: 29427586

Group type: EXPERIMENTAL
Intervention: Thiamidol (isobutylamido thiazolyl resorcinol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroquinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kojic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroquinone and arbutin
Number of subjects: 0
Study: 27577517

Group type: EXPERIMENTAL
Intervention: Dual-energy spectral CT with iodixanol (270 mg I/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional high iodine contrast agent iohexol (350 mg I/mL)
Number of subjects: 40
Study: 24788494

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional surgery (CONV)
Number of subjects: 192
Study: 23759172

Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: sertraline (50 mg/d)
Number of subjects: 118

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 118
Study: 20071998

Group type: EXPERIMENTAL
Intervention: Balance training in a balance trainer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 18191574

Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 69
Study: 15258611

Group type: EXPERIMENTAL
Intervention: travoprost 0.0015%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: brinzolamide 1%
Number of subjects: 90

Group type: COMPARATOR
Intervention: balanced salt solution
Number of subjects: 90
Study: 14512873

Group type: EXPERIMENTAL
Intervention: IL-10 therapy (SQ IL-10 given daily or thrice weekly)
Number of subjects: 30
Study: 10576234

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate plus vaginal misoprostol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 21
Study: 8561109

Group type: EXPERIMENTAL
Intervention: Rapid hepatitis B vaccination schedule (0, 1, and 2 months)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard hepatitis B vaccination schedule (0, 1, 6 months)
Number of subjects: 234
Study: 1984534

Group type: EXPERIMENTAL
Intervention: Mefloquine every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine phosphate weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine with daily proguanil hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine dosing regimen
Number of subjects: 0
Study: 30688873

Group type: EXPERIMENTAL
Intervention: Bilateral resistance training (back squat)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (step-up)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (comparison)
Number of subjects: 33
Study: 30029896

Group type: EXPERIMENTAL
Intervention: 3HP (weekly rifapentine plus isoniazid)
Number of subjects: 263

Group type: COMPARATOR
Intervention: 9H (9-month daily isoniazid)
Number of subjects: 263
Study: 26796802

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhG‐CSF 5 μg/kg
Number of subjects: 0
Study: 24883322

Group type: EXPERIMENTAL
Intervention: AA-PRP injection
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 22242645

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethyl ester formulation 1 (12 g single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethyl ester formulation 2 (12 g single dose)
Number of subjects: 0
Study: 19840120

Group type: EXPERIMENTAL
Intervention: Rimonabant (non-reimbursed diet drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimonabant (reimbursed diet drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular contacts with pharmaceutical sales representatives
Number of subjects: 0
Study: 17464747

Group type: EXPERIMENTAL
Intervention: Test patches (two types)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Negative control patch (0.9% sodium chloride)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Positive control patch (0.1% sodium lauryl sulphate)
Number of subjects: 29
Study: 15893044

Group type: EXPERIMENTAL
Intervention: Adaptation exercise
Number of subjects: 359

Group type: COMPARATOR
Intervention: No adaptation exercise (control)
Number of subjects: 359
Study: 12141889

Group type: EXPERIMENTAL
Intervention: Entacapone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (levodopa)
Number of subjects: 0
Study: 9659490

Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing using a distraction apparatus
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fracture table nailing
Number of subjects: 24
Study: 7652032

Group type: COMPARATOR
Intervention: Caffeine 0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (various dosages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time of Day (TOD)
Number of subjects: 0
Study: 2496668

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + Ftorafur (FT) + Krestin (PSK)
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + PSK
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + Ftorafur (FT)
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) + PSK
Number of subjects: 3650

Group type: EXPERIMENTAL
Intervention: MMC + FT + PSK + Picibanil (OK-432)
Number of subjects: 3650
Study: 356247

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 50 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen 250 mg b.i.d.
Number of subjects: 0
Study: 31950036

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 25
Study: 27696551

Group type: EXPERIMENTAL
Intervention: Pethidine hydrochloride (35 mg) given i.v.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam (i.v. maintaining Ramsay score of 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 120
Study: 25546476

Group type: EXPERIMENTAL
Intervention: Kinetic oscillation stimulation (KOS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23582152

Group type: COMPARATOR
Intervention: Patients with IBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with IBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Controls (HCs)
Number of subjects: 0
Study: 21820163

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (176 μg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19438994

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% in a new gel formulation
Number of subjects: 123
Study: 17472817

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simvastatin 80 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atorvastatin and Simvastatin (dose ratios between 1:2 and 1:4)
Number of subjects: 18
Study: 15619496

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg IV/oral every 12 hours
Number of subjects: 135

Group type: COMPARATOR
Intervention: Vancomycin 1 g IV every 12 hours
Number of subjects: 135
Study: 11391326

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10322832

Group type: EXPERIMENTAL
Intervention: Busui Shengxue Capsule (BSSXC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Busui Shengxue Capsule (BSSXC) with IL‐3, IL‐6, IL‐11
Number of subjects: 35
Study: 8490109

Group type: EXPERIMENTAL
Intervention: Brofaromine hydrochloride 75 mg after overnight fasting
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brofaromine hydrochloride 75 mg after a fat- and protein-rich breakfast
Number of subjects: 8
Study: 3688070

Group type: EXPERIMENTAL
Intervention: Aggressive management of early labor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 0
Study: 30748125

Group type: EXPERIMENTAL
Intervention: High-fat, high-calorie meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose calcium carbonate (3000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose magnesium hydroxide/aluminum hydroxide (1600 mg each)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose calcium carbonate (1250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium hydroxide/aluminum hydroxide (800 mg each)
Number of subjects: 0
Study: 28763003

Group type: EXPERIMENTAL
Intervention: RTD (Ready-to-Drink beverage with caffeine 200 mg, β-alanine 2.1 g, arginine nitrate 1.3 g, niacin 65 mg, folic acid 325 mcg, Vitamin B12 45 mcg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: RTD (Ready-to-Drink beverage)
Number of subjects: 25

Group type: COMPARATOR
Intervention: PLA (Placebo beverage with 12 g of dextrose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: PLA (Placebo beverage)
Number of subjects: 25